NIDA offers a broad range of funding opportunities that target all stages of biomedical product development (Ideation, Feasibility, and Product Development):
NIDA Entrepreneurial Development Funding Opportunities
To help researchers and entrepreneurs get their idea off the ground, NIDA offers several educational and training programs.
| Title | Links | Key Details |
|---|---|---|
| 2023 “100,00 to Start an SUD Startup” Challenge - A 6-month biomedical mentoring program that aims to test the premise of research ideas that can be fostered into biotech startups. |
|
Due date: Fall 2023 Award Budget: $10,000 |
| Entrepreneurship Training Program for Substance Use Researchers - Hybrid online and in-person training courses to teach diverse entrepreneurship and product development skills through case studies and dynamic presentations from leaders in the substance use disorder field. |
|
Due dates: L-SPRINT: March 1, 2023 I4SUD: June 30, 2023 MIT: Fall 2023 Award Budget: Cost of travel, room, and board |
NIH SBIR and STTR Omnibus Solicitation
To help companies develop their innovative ideas, NIDA participated in the SBIR and STTR omnibus solicitation. The funding opportunity targets PI-initiated research (your own idea) that has the potential for technology commercialization and impact on public health.
| Title | Links | Key Details |
|---|---|---|
| 2023 NIH SBIR/STTR Omnibus Solicitation (expected to be re-issued Summer 2023) |
Standard due dates: January 5, April 5, and September 5 Award Budget: Ranges from $150,000 to $320,000 for Phase I, and $1 million to $2.5 million for Phase II |
|
| 2023 NIH SBIR/STTR Omnibus Solicitation (expected to be re-issued Summer 2023) |
Standard due dates: January 5, April 5, and September 5 Award Budget: Ranges from $150,000 to $320,000 for Phase I, and $1 million to $2.5 million for Phase II |
Although NIDA considers a range of innovative technologies targeting substance use disorders, specific topic of interest for the NIDA SBIR/STTR programs include the following:
- Biomarker development for SUDs
- SUD drug discovery and development
- Technologies for safe and controlled methadone dispensing for use as a “take-home”
- FDA-regulated medical therapeutic and diagnostic devices for SUD
- Technological approaches to address stigma associated with SUDs
- Digital Health Technologies to Address the Social Determinants of Health in context of SUDs
- New technological approaches for the investigation, diagnosis, and certification of deaths related to drug overdose
NIDA Targeted SBIR and STTR Funding Opportunities
These targeted SBIR/STTR grant solicitations are focused on specific research areas of interest to NIDA. These NOFOs can be RFAs (Requests for Applications); PAs, PARs, and PASs (different kinds of Program Announcements); and RFPs (Requests for Proposals).
| Title | Links | Key Details |
|---|---|---|
| Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) |
|
Due dates: August 15, 2023; February 14, 2024; August 13, 2024; February 14, 2025 Award Budget: Total funding support may not exceed $320,000 for Phase I awards and $2,500,000 for Phase II awards. |
| Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment |
|
Due date: November 10, 2023 Award Budget: Budgets up to $295,924 total costs for Phase I and up to $1,972,828 total costs for Phase II. For projects falling under the NIDA SBA waiver topics, total costs may not exceed $320,000 for Phase I awards and $2,500,000 for Phase II awards. |
| Blueprint Medtech: Small Business Translator |
|
Due dates: June 19, 2023 (UG3/UH3); June 20, 2023 (U44); Both: October 18, 2023; February 20, 2024, June 20, 2024 Award Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project and should only cover the work that will be performed by the PD/PI and their staff. |
| Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System |
|
Due dates: August 9, 2023; February 9, 2024 Award Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project and should only cover the work that will be performed by the PD/PI and their staff. |
| Small Business Transition Grant For Early Career Scientists |
|
Due date: August 21, 2023 Award Budget: Total costs normally may not exceed $295,924 for Phase I awards and $1,972,928 for Phase II awards. For specific topics, NIH may exceed these total award amounts. |
Notices of Special Interest
NIDA also participates in Notices of Special Interest (NOSIs), which highlights specific topics or areas of interest. These NOSIs may be released by NIDA or other Institutes/Centers at NIH.
- HIV Drug Resistance Assays and Actionable Data Dissemination Strategies (NOT-AI-21-056)
- BRAIN Initiative: Translation of Groundbreaking Technologies from Early-stage Development through Early Clinical Study via Blueprint MedTech (NOT-NS-22-052)
- HEAL Initiative: Clinical Translation of Diagnostic and Therapeutic Devices via Blueprint MedTech (NOT-NS-23-002)
- Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (NOT-OD-21-100)
- Priority Research Opportunities in Crisis Response Services (NOT-MH-22-110)
- Research on Strategies to Enhance Mental Health Interventions and Services within Employment and Job Training Settings (NOT-MH-21-230)
- Translation of BRAIN Initiative Technologies to the Marketplace (NOT-MH-21-125)
- Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research (NOT-CA-22-037)
- Archived Funding Opportunities
-
- Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development
- SBIR (RFA-DA-22-019)
- STTR (RFA-DA-22-021)
- Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction
- SBIR (RFA-DA-22-001)
- HEAL Initiative: America's Startups and Small Businesses Build Technologies to Stop the Opioid Crisis
- SBIR (RFA-DA-19-019)
- STTR (RFA-DA-19-020)
- Digital Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders
- SBIR (RFA-DA-21-031)
- STTR (RFA-DA-21-032)
- Novel Approaches to Decrease Stigma of Substance Use Disorders in Order to Facilitate Prevention, Treatment, and Supporting During Recovery
- SBIR (RFA-DA-21-015)
- STTR (RFA-DA-21-016)
- Rapid Assessment of Drug Abuse: Smart City Tools
- SBIR (RFA-DA-20-020)
- STTR (RFA-DA-20-021)
- Digital Health Technologies to Address the Social Determinants of Health in Context of Substance Use Disorders (SUD)
- SBIR (RFA-DA-20-017)
- STTR (RFA-DA-20-018)
- Blockchain Technology to Improve SUD Care
- SBIR (RFA-DA-20-011)
- STTR (RFA-DA-20-012)
- Virtual Reality Tools to Enhance Evidence Based Treatment of Substance Use Disorders
- SBIR (RFA-DA-19-032)
- STTR (RFA-DA-19-033)
- Mobile Technologies Extending Reach of Primary Care for Substance-Use-Disorders
- SBIR (RFA-DA-19-021)
- STTR (RFA-DA-19-022)
- Analytical Tools and Approaches for (Multidimensional) Scholarly Research Assessment and Decision Support in the Biomedical Enterprise
- SBIR ([RFA-DA-19-030)
- STTR (RFA-DA-19-031)
- Development of a Device to Objectively Measure Pain
- SBIR (RFA-DA-18-012)
- STTR (RFA-DA-18-013)
- Nasal Delivery of CNS Therapeutics
- SBIR (RFA-DA-18-006)
- STTR (RFA-DA-18-007)
- Wearable to Track Recovery and Relapse Factors for People w/ Addiction
- SBIR (RFA-DA-18-010)
- Extracellular Vesicle Tools, Technologies, and Products for Neuroscience Research
- SBIR (RFA-DA-17-009)
- STTR (RFA-DA-17-008)
- Improved Technologies and Ligands for Non-invasive Brain Imaging
- SBIR (RFA-DA-17-011)
- STTR (RFA-DA-17-010)
- Laboratory and Diagnostic Tools to Advance Microbiome-Brain Research
- SBIR (RFA-DA-17-017)
- STTR (RFA-DA-17-016)
- Tools and Services for Designing Methodologically Rigorous Animal Studies
- SBIR (RFA-DA-16-003)
- STTR (RFA-DA-16-002)
- Tools for Monitoring and Manipulating Modified RNAs in the Nervous System
- SBIR (RFA-DA-15-001)
- STTR (RFA-DA-15-002)
- Abuse-Resistant and Abuse-Deterrent Formulations and Devices to Avoid the Abuse, Misuse and Diversion of Prescription Opioids by Patients (SBIR)
- SBIR (RFA-DA-14-013)
- Pharmacological Development of Treatment Agents and Formulations for Tobacco Dependence
- STTR (RFA-DA-11-004)
- Leveraging Artificial Intelligence (AI) tools for Substance Use Disorders (SUD) drug discovery and development